Bristol-Myers Squibb Co.

NYSE:BMY  
58.35
+0.65 (+1.13%)
4:00:02 PM EDT: $58.36 +0.01 (+0.02%)
Products, Litigation

Cipla Ltd Says Settlement Of Revlimid (Lenalidomide) Capsules Patent Litigation

Published: 12/11/2020 14:36 GMT
Bristol-Myers Squibb Co. (BMY) - Cipla Ltd Says Announces Settlement of Revlimid® (lenalidomide) Capsules Patent Litigation.
Cipla Ltd - Celgene Agreed to Provide Co With License to Patents Needed to Make, Sell Some Volume-limited Amounts of Generic Lenalidomide in U.S.cipla - Ability to Market Lenalidomide in U.S. to Be Contingent on Obtaining Approval of Abbreviated New Drug Application.